WEBULL
News
XOMA
26.06
+0.27%
0.07
XOMA Royalty Corporation announces $0.53906 Series A and $0.52344 Series B preferred stock dividends
Reuters · 6d ago
Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends
Dow Jones · 6d ago
Weekly Report: what happened at XOMA last week (1215-1219)?
Weekly Report · 6d ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Barchart · 6d ago
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20 05:44
Strategic Acquisitions and Partnerships Drive Xoma’s Growth: A Buy Recommendation
TipRanks · 12/16 17:05
Generation Bio price target lowered to $5.50 from $7 at Wedbush
TipRanks · 12/16 14:10
Generation Bio downgraded to Hold from Buy at Jefferies
TipRanks · 12/16 10:10
XOMA Royalty to acquire Generation Bio
Seeking Alpha · 12/15 22:28
Xoma Royalty to Buy Generation Bio
Dow Jones · 12/15 22:22
Xoma to acquire Generation Bio for $4.2913 per share
TipRanks · 12/15 22:05
XOMA Royalty To Acquire Generation Bio Co. For A Cash Price Of $4.2913 Per Share At The Closing Of The Merger
Benzinga · 12/15 22:02
XOMA Royalty to Acquire Generation Bio for $4.29 Per Share Plus CVR
Reuters · 12/15 22:00
GENERATION BIO CO - XOMA ROYALTY TO BUY GENERATION BIO FOR $4.2913 PER SHARE
Reuters · 12/15 22:00
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Contineum Therapeutics, Inc. Class A (CTNM), Xoma (XOMA) and Applied Therapeutics (APLT)
TipRanks · 12/15 14:41
Weekly Report: what happened at XOMA last week (1208-1212)?
Weekly Report · 12/15 09:43
XOMA Royalty Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/11 19:03
XOMA Royalty Price Target Cut to $97.00/Share From $104.00 by HC Wainwright & Co.
Dow Jones · 12/11 19:03
HC Wainwright & Co. Maintains Buy on XOMA Royalty, Lowers Price Target to $97
Benzinga · 12/11 18:53
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.